SYDNEY<\/span><\/span>, April 8, 2022<\/span><\/span> \/PRNewswire\/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late stage, oncology-focused drug development company, is pleased to announce two presentations detailing the ongoing phase I study of the company’s investigational novel drug, EVT801, a selective VEGFR3 inhibitor with potential application in a variety of cancers.<\/p>\n

\n<\/p><\/div>\n

The poster presentations describe the study design and a highly innovative biomarker strategy employed in the study and are being delivered at the Annual Meeting of the American Association for Cancer Research (AACR), held in New Orleans, LA<\/span> from 8 \u2013 13 April 2022<\/span>.<\/p>\n

Key Points<\/b><\/p>\n

\n
EVT801 is a novel inhibitor of VEGFR3, a receptor involved in the formation of new lymphatic vessels around a growing tumour. Preclinical data has demonstrated that EVT801 is able to inhibit the growth and spread of new tumours and combines synergistically with immuno-oncology therapies.<\/li>\n
EVT801 was licensed to Kazia by Evotec SE (FRA: EVT), a leading European drug discovery and development company, in April 2021<\/span>. The two companies have collaborated to launch a phase I clinical trial with EVT801 in patients with advanced cancer (NCT05114668), which commenced recruitment in November 2021<\/span>.<\/li>\n
In addition to characterizing the safety, tolerability, and pharmacokinetics of the drug, the phase I study employs a suite of highly innovative biomarkers to better characterize the potential efficacy of EVT801, and to identify patients who may benefit most. These novel strategies are the primary subject matter of the posters presented at AACR.<\/li>\n<\/ul>\n
Kazia CEO, Dr James Garner<\/span>, commented, "EVT801 is an exciting new drug candidate with enormous potential, and it is fitting that the study we launched in partnership with Evotec is similarly innovative. The sophisticated biomarker strategies employed in this study should give us a much richer and more detailed understanding of the drug than is usual at this stage of development, and those insights should in turn allow us to optimize future trials to enhance the likelihood of success for EVT801."<\/p>\n
The posters will be presented in person at the meeting by Dr John Friend<\/span> (Kazia Therapeutics), Dr Pierre Fons<\/span> (Evotec), and Dr Marie Mandron<\/span> (Evotec).<\/p>\n
The phase I clinical trial of EVT801 is currently recruiting patients at two sites in France<\/span>. Initial data is provisionally expected in 2H CY2022.<\/p>\n
Summary of Abstracts<\/b><\/p>\n
SESSION PO.CT01.03 – Phase I Trials in Progress 1<\/u><\/p>\n
April 12, 2022<\/span> \u2013 9:00am-12:30pm<\/span><\/p>\n
Abstract CT206 \/ 6<\/b> - EVT801, a novel selective VEGFR-3 inhibitor targeting tumor angiogenesis, started enrollment for its phase I first-in-human study<\/p>\n
Carlos Gomez Roca<\/span>, Philippe Cassier<\/span>, Marie Mandron<\/span>, Myriam Estrabaut, Nathalie Delesque-Touchard, Adam C. Smith<\/span>, Amy Klawitter<\/span>, Leesa Gentry<\/span>, Pierre Fons<\/span>, Michael R. Paillasse, Lise Davenne, Michael Fitzgerald<\/span>, James Garner<\/span>, Jean-Pierre Delord<\/span>.<\/p>\n
Oncopole IUCT, Toulouse, France<\/span>; Centre Léon Bérard, Lyons, France<\/span>; Evotec, Toulouse, France<\/span>; Evotec, Princeton, NJ<\/span>; Kazia Therapeutics, Sydney, Australia<\/span><\/i><\/p>\n
SESSION PO.TB05.01 – Tumor Angiogenesis<\/u><\/p>\n
April 12, 2022<\/span> \u2013 1:30pm-5:00pm<\/span><\/p>\n
Abstract 3203 \/ 1<\/b> - Cutting edge biomarkers strategy to provide early insights into activity of EVT-801, a novel selective VEGFR-3 inhibitor that targets tumor angiogenesis during the FIH clinical trial<\/p>\n
Michael R. Paillasse, James Garner<\/span>, Michael Fitzgerald<\/span>, Lise Davenne, Pierre-Benoit Ancey<\/span>, Celine Poussereau-Pomie, Michael Esquerre<\/span>, Gaelle Badet<\/span>, Joel Tuyaret, Marie Mandron<\/span>, Philippe Rochaix, Maha Ayyoub, Clara Maria Scarlata<\/span>., Christine Ménétrier-Caux, Christophe Caux<\/span>, Philippe Cassier<\/span>, Jean-Pierre Delord<\/span>, Carlos Gomez Roca<\/span>, Pierre Fons<\/span>.<\/p>\n
Evotec, Toulouse, France<\/span>; Kazia Therapeutics Limited, Sydney, Australia<\/span>; Oncopole IUCT, Toulouse, France<\/span>; Centre Léon Bérard, Lyon<\/span>, Franc<\/i><\/p>\n
About Kazia Therapeutics Limited <\/b><\/p>\n
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in Sydney, Australia<\/span>.<\/p>\n
Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K \/ Akt \/ mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, paxalisib commenced recruitment to GBM AGILE, a pivotal study in glioblastoma, in January 2021<\/span>. Eight additional studies are active in various forms of brain cancer. Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018<\/span>, and Fast Track Designation for glioblastoma by the US FDA in August 2020<\/span>. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020<\/span>.<\/p>\n
Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021<\/span>. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno-oncology agents. A phase I study commenced recruitment in November 2021<\/span>.<\/p>\n
For more information, please visit www.kaziatherapeutics.com<\/a> or follow us on Twitter @KaziaTx.<\/p>\n
This document was authorized for release to the ASX by James Garner<\/span>, Chief Executive Officer, Managing Director.<\/p>\n
<\/div>\n","protected":false},"excerpt":{"rendered":"
SYDNEY, April 8, 2022 \/PRNewswire\/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late stage, oncology-focused drug development company,…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[105],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts\/100850"}],"collection":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/comments?post=100850"}],"version-history":[{"count":0,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts\/100850\/revisions"}],"wp:attachment":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/media?parent=100850"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/categories?post=100850"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/tags?post=100850"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}